Power Law company profile

Hansa Biopharma

Biotech & Life Sciences · Lund Municipality, Sweden · Founded 2007 · IPO 2007 Colt

Develops immunomodulating therapies for rare autoimmune conditions, transplant rejection and cancer

Valuation

$385M

Market cap · May/2026

Revenue

$27M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Global footprint

Where Hansa Biopharma has talent and traffic

Workforce by country

🇸🇪 Sweden · Lund Municipality HQ

Book a demo for the full country breakdown

Web traffic by country

9.8K monthly visits
across markets

🇯🇴 Jordan90.8%

🇺🇸 United States30.6%

🇸🇪 Sweden29.6%

🇮🇳 India18.4%

🇩🇰 Denmark6.1%

Top 5 markets shown

Market sentiment

What the market is saying about Hansa Biopharma

An AI-synthesized read of the highest-engagement posts about Hansa Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hansa Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles